AxoGen and Blueprint Medicines Help Opaleye Return 91% Over the Last Year
James A. Silverman founded Opaleye Management back in 1996 and it was formerly known as Risk/Reward Capital.
Hedge Fund - Opaleye Management
Get Email AlertsJames A. Silverman Bio, Returns, AUM, Net Worth
Manager biography is currently missing.
Fund Profile
Filing Period:
| Fund Name: | Opaleye Management |
| Manager | James A. Silverman |
| Portfolio Value | $321,996,000 |
| Change This QTR | +0.68% |
Top 13F Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Security | Ticker | Shares | Value (x$1000) | Activity | % Port | History |
|---|---|---|---|---|---|---|---|
| 1. | OCUL | 5,974,800 | $29,575 | 9.18% | |||
| 2. | CDXS | 1,345,000 | $27,734 | 8.61% | |||
| 3. | CMRX | 5,903,450 | $27,038 | +6% | 8.39% | ||
| 4. | Harrow Health Inc | 3,291,343 | $22,447 | +1% | 6.97% | ||
| 5. | CRNX | 693,000 | $15,211 | -5% | 4.72% |
Latest 13D & 13G Filings
| Symbol | Company | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2022-06-10 | ||||
| 2022-06-03 | ||||
| 2022-02-18 | ||||
| 2022-02-01 | ||||
| 2022-02-01 |
News, Interviews and Investor Letters
13G Filing: Opaleye Management and Inotek Pharmaceuticals Corp (ITEK)
Inotek Pharmaceuticals Corp (NASDAQ:ITEK): James A. Silverman's Opaleye Management filed an amended 13D.
You can check out Opaleye Management's latest holdings and filings here.
13G Filing: Opaleye Management and Tonix Pharmaceuticals Holding Corp. (TNXP)
You can access the original SEC filing by clicking here.
This Healthcare Fund Just Had A Huge Q3: Here's How
The mainstream media likes taking shots at hedge funds because they are easy targets.
More Than 60% Returns For These Two Hedgies' Favorite Health Care Picks
The health care sector has appreciated by nearly 30% over the past year. We decided to take a look at three companies that two health care-focused funds, namely James A.
